Praxis Precision Epilepsy Drug Fails Late-Stage Study
Praxis Precision Medicines announced that its experimental drug vormatrigine failed to meet the primary goal of reducing seizure frequency in a mid-to-late stage study. The company has paused enrollment in a second trial while shares declined over 12% in extended trading following the news.
Xurve View
Insights:
Xurve View
Praxis Precision Medicines shares fell 12% in extended trading after its experimental epilepsy drug failed a mid-to-late stage study. The drug, vormatrigine, did not meet its primary goal of reducing monthly seizure frequency in adults with focal onset seizures. The failure forces a reassessment of the clinical program and pauses further enrollment in an ongoing secondary trial.
